Merck and Ridgeback’s molnupiravir received U.S. FDA EUA for treatment of high-risk adults with COVID-19
On Dec. 23, 2021, Merck and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) had…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science News | Therapeutics | Vaccine
Merck and Ridgeback Biotherapeutics provided update on results from MOVe-OUT study of Molnupiravir in adults with COVID-19
On Nov. 26, 2021, Merck provided an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral…
Merck announced supply agreement with U.S. Government for molnupiravir, an Investigational oral antiviral treatment of COVID-19
On Jun. 8, 2021, Merck announced it had entered into a procurement agreement with the U.S. government for…
Merck announced licensing agreements with Indian manufacturers to expand access to molnupiravir for treatment of COVID-19
On Apr. 27, 2021, Merck announced the company had entered into non-exclusive voluntary licensing agreements for molnupiravir with…